Application of vasoactive and matrix-modifying drugs can improve polyplex delivery to tumors upon intravenous administration

J Control Release. 2016 Jun 28:232:20-8. doi: 10.1016/j.jconrel.2016.04.011. Epub 2016 Apr 9.

Abstract

Low efficacy of cationic polymer-based formulations (polyplexes) for systemic gene delivery to tumors remains the crucial concern for their clinical translation. Here we show that modulating the physiological state of a tumor using clinically approved pharmaceuticals can improve delivery of intravenously injected polyplexes to murine melanoma tumors with different characteristics. Direct comparison of drugs with different mechanisms of action has shown that application of nitroglycerin or losartan improved extravasation and tumor uptake of polyplex nanoparticles, whereas angiotensin II had almost no effect on polyplex accumulation and microdistribution in the tumor tissue. Application of nitroglycerin and losartan caused from 2- to 6-fold enhanced efficacy of polyplex-mediated gene delivery depending on the tumor model. The results obtained on polyplex behavior in tumor tissues depending on physiological state of the tumor can be relevant to optimize delivery of polyplexes and other nanomedicines with similar physicochemical properties.

Keywords: Gene delivery; Nanoparticle extravasation; Polyplexes; Tumor uptake; Tumor vasculature.

MeSH terms

  • Administration, Intravenous
  • Angiotensin II / administration & dosage
  • Angiotensin II / pharmacokinetics
  • Angiotensin II / pharmacology
  • Animals
  • Cell Line, Tumor
  • Collagen Type I / metabolism
  • DNA / administration & dosage
  • Drug Delivery Systems*
  • Female
  • Gene Expression Regulation, Neoplastic
  • Gene Transfer Techniques*
  • Green Fluorescent Proteins / genetics
  • Losartan / administration & dosage
  • Losartan / pharmacokinetics
  • Losartan / pharmacology
  • Luciferases, Firefly / genetics
  • Melanoma, Experimental / genetics
  • Melanoma, Experimental / metabolism
  • Melanoma, Experimental / physiopathology
  • Melanoma, Experimental / therapy*
  • Mice, Inbred C57BL
  • Mice, Inbred DBA
  • Nanoparticles / administration & dosage
  • Nitroglycerin / administration & dosage
  • Nitroglycerin / pharmacokinetics
  • Nitroglycerin / pharmacology
  • Oligopeptides / administration & dosage
  • Oligopeptides / pharmacokinetics
  • Polyethylene Glycols / administration & dosage
  • Polyethylene Glycols / pharmacokinetics
  • Polyethylene Glycols / pharmacology
  • Polyethyleneimine / administration & dosage
  • Polyethyleneimine / analogs & derivatives
  • Polyethyleneimine / pharmacokinetics
  • Polyethyleneimine / pharmacology
  • Receptor, Melanocortin, Type 1 / metabolism
  • Regional Blood Flow / drug effects
  • Vasoconstrictor Agents / administration & dosage
  • Vasoconstrictor Agents / pharmacokinetics
  • Vasoconstrictor Agents / pharmacology
  • Vasodilator Agents / administration & dosage
  • Vasodilator Agents / pharmacokinetics
  • Vasodilator Agents / pharmacology

Substances

  • Collagen Type I
  • Oligopeptides
  • Receptor, Melanocortin, Type 1
  • Vasoconstrictor Agents
  • Vasodilator Agents
  • enhanced green fluorescent protein
  • poly(ethylene glycol)-co-poly(ethyleneimine)
  • Angiotensin II
  • Green Fluorescent Proteins
  • Polyethylene Glycols
  • Polyethyleneimine
  • DNA
  • Luciferases, Firefly
  • Nitroglycerin
  • Losartan